Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 36 citing articles:

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia
Cooper Quartermaine, Sanam Ghazi, Aneeq Yasin, et al.
JACC CardioOncology (2023) Vol. 5, Iss. 5, pp. 570-590
Open Access | Times Cited: 44
Advancements in small molecule drug design: A structural perspective
Ke Wu, Eduard Karapetyan, John V. Schloss, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 10, pp. 103730-103730
Open Access | Times Cited: 35
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
Thomas E. Lew, Adrian Minson, Michael Dickinson, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 2, pp. e142-e154
Closed Access | Times Cited: 16
Molecular Precision Medicine: Multi-Omics-Based Stratification Model for Acute Myeloid Leukemia
Teng Wang, Siyuan Cui, Chunyi Lyu, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e36155-e36155
Open Access | Times Cited: 6
Bcl-2 family inhibitors sensitize human cancer models to therapy
Elisabetta Valentini, Marta Di Martile, Matteo Brignone, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 7
Open Access | Times Cited: 14
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon
Thomas E. Lew, Rory Bennett, Victor S. Lin, et al.
Blood Advances (2024) Vol. 8, Iss. 6, pp. 1439-1443
Open Access | Times Cited: 5
Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax
Thao M. Nguyen, Paul Joyce, David M. Ross, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 209-209
Open Access | Times Cited: 5
Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia
Øystein Bruserud, Håkon Reikvam
Cancers (2023) Vol. 15, Iss. 14, pp. 3711-3711
Open Access | Times Cited: 11
Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting
Jieyu Xu, Honghu Zhu
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells
Marten A. Fischer, Al‐Hassan M. Mustafa, Kristin Hausmann, et al.
Journal of Advanced Research (2023) Vol. 60, pp. 201-214
Open Access | Times Cited: 9
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
Yang Yang, Yamin Shu, Guosong Chen, et al.
PLoS ONE (2022) Vol. 17, Iss. 12, pp. e0278725-e0278725
Open Access | Times Cited: 15
Combined Delivery of miR-15/16 through Humanized Ferritin Nanocages for the Treatment of Chronic Lymphocytic Leukemia
Francesca Romana Liberati, Sara Di Russo, Lorenzo Barolo, et al.
Pharmaceutics (2024) Vol. 16, Iss. 3, pp. 402-402
Open Access | Times Cited: 2
Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies
Elizabeth Smyth, Chan Y. Cheah, John F. Seymour
Cancer Treatment Reviews (2023) Vol. 113, pp. 102510-102510
Closed Access | Times Cited: 6
Senotherapy, cancer, and aging
Lodovico Balducci, Claire Falandry, S. Monfardini
Journal of Geriatric Oncology (2023) Vol. 15, Iss. 4, pp. 101671-101671
Closed Access | Times Cited: 6
Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?
Mariana Tannoury, Delphine Garnier, Santos A. Susín, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6026-6026
Open Access | Times Cited: 8
Platycodin D induces proliferation inhibition and mitochondrial apoptosis in diffuse large B-cell lymphoma
Pu Liu, Mengting Zhao, Lin Ye, et al.
Experimental Hematology (2023) Vol. 123, pp. 46-55.e1
Closed Access | Times Cited: 4
The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies
Paweł Robak, Magdalena Witkowska, Anna Wolska, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 10, pp. 1065-1076
Closed Access | Times Cited: 4
Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience
Francesco Angotzi, Federica Lessi, Matteo Leoncin, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: from interconnected signalling pathways to therapeutic strategies
Brigitte Bauvois, Florence Nguyen‐Khac, Hélène Merle‐Béral, et al.
Biochimie (2024)
Closed Access | Times Cited: 1
Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease
Thomas E. Lew, Edward R. Scheffer Cliff, Michael Dickinson, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 11, pp. 1792-1800
Closed Access | Times Cited: 3
Venetoclax Synergizes Sunitinib in Renal Cell Carcincoma through Inhibition of Bcl-2
Yuanjia Tang, Tao Song, Liangkui Gao, et al.
Anti-Cancer Agents in Medicinal Chemistry (2023) Vol. 23, Iss. 18, pp. 2027-2034
Closed Access | Times Cited: 3
The Value of Neutrophil Gelatinase-Associated Lipocalin Receptor as a Novel Partner of CD38 in Chronic Lymphocytic Leukemia: From an Adverse Prognostic Factor to a Potential Pharmacological Target?
Brigitte Bauvois, Élise Chapiro, Claire Quiney, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2335-2335
Open Access | Times Cited: 3
Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells
Marten A. Fischer, Al‐Hassan M. Mustafa, Kristin Hausmann, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Dysregulation of BCL-2 family proteins in blood neoplasm: therapeutic relevance of antineoplastic agent venetoclax
Faris J. Tayeb
Exploration of Medicine (2024), pp. 331-350
Open Access
Advancements in B‐Cell Non‐Hodgkin’s Lymphoma: From Signaling Pathways to Targeted Therapies
Abdullah Alfaifi, Salem Bahashwan, Mohammed Alsaadi, et al.
Advances in Hematology (2024) Vol. 2024, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top